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Caspase-14 is an important protease in the proper formation of a fully functional skin barrier. Newborn mice that
are deficient in caspase-14 exhibit increased transepidermal water loss and are highly sensitive to UVB-induced
photodamage. Decreased caspase-14 expression and incomplete caspase-14 processing in lesional psoriatic
parakeratotic stratum corneum has been reported previously. In this study, we show that caspase-14-deficient
skin frequently displays incompletely cornified cells in the transitional zone between the granular and the
cornified layers, pointing to a delay in cornification. We also demonstrate that after challenge of epidermal
permeability barrier function by repetitive acetone treatment, a higher incidence of large parakeratotic plaques
was observed in caspase-14-deficient skin. Furthermore, caspase-14-deficient mice are more prone than control
mice to the development of parakeratosis upon induction of psoriasis-like dermatitis by imiquimod treatment.
These results show that lack of caspase-14 expression predisposes to the development of parakeratosis and that
caspase-14 has an important role in keratinocyte terminal differentiation and the maintenance of normal stratum
corneum, especially in conditions causing epidermal hyperproliferation.
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INTRODUCTION
Skin barrier function is crucial for terrestrial mammalian life,
as it protects the body against water loss. The epidermis
mainly consists of keratinocytes, which differentiate to pro-
duce a functional skin barrier. An impaired balance between
keratinocyte proliferation and differentiation causes a variety
of skin disorders, including psoriasis, dermatitis, and skin
cancer. Recently, it has become clear that defects in the
epidermal barrier can underlie the development of inflamma-
tory skin diseases (Proksch et al., 2008). The epidermal
permeability barrier function is pivotally maintained by two
components of the stratum corneum (SC), namely the
cornified envelopes (CEs), which are the end products of
keratinocytes undergoing terminal differentiation, and the
lipid-enriched extracellular matrix enshrouding these CEs.
Caspases are cysteinyl aspartate–specific proteases that
exert their functions during apoptosis and inflammation
(Lamkanfi et al., 2003). Recently, it has become clear that
caspases also have important functions in maintaining
epidermal homeostasis. Caspase-14 is the sole caspase that
is fully processed during physiological keratinocyte terminal
differentiation (Fischer et al., 2004; Raymond et al., 2007). Its
expression is constrained to the suprabasal layers of the
epidermis and the thymic Hassall’s bodies in mice and
humans (Eckhart et al., 2000; Lippens et al., 2000), and to
the forestomach of rodents (Lippens et al., 2003; Denecker
et al., 2007). These tissues contain cornified epithelial cells
and express additional terminal differentiation markers such as
filaggrin and loricrin (Jarnik et al., 1996). Caspase-14-deficient
mice show defects in skin barrier function reflected in a higher
transepidermal water loss (TEWL) and increased sensitivity to
UVB-induced photodamage. Identification of (pro)filaggrin as
the first, and currently only, in vivo substrate of caspase-14
provides further evidence that caspase-14 has a crucial role in
epidermal barrier function (Denecker et al., 2007; Hoste et al.,
2011). We have previously shown that caspase-14 expression
is significantly downregulated in parakeratotic plaques of
psoriatic patients (Lippens et al., 2000). Treatment of these
patients with vitamin D3 analogs or with epigallocatechin-3-
gallate, two inducers of caspase-14 expression, resulted in
clinical improvement accompanied by increased caspase-14
expression levels (Lippens et al., 2004; Hsu et al., 2007).
Furthermore, in parakeratotic human SC, caspase-14 is present
partly in its zymogen form (Fischer et al., 2004; Raymond
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et al., 2007), whereas in normal SC, caspase-14 is completely
processed and uniquely present in its activated state. The
importance of caspases in skin homeostasis has been rein-
forced by the finding that mice lacking epidermal caspase-8
exhibit a strong inflammatory skin phenotype (Kovalenko
et al., 2009; Lee et al., 2009). However, mechanistically,
caspase-8 and caspase-14 are acting at different levels. A low
level of caspase-8 activity is required to prevent RIPK1
(receptor interacting kinase)- and RIK3-mediated necrotic
cell death that leads to skin inflammation (Kaiser et al.,
2011), whereas caspase-14 is required for filaggrin
degradation during keratinocyte cornification (Denecker
et al., 2007; Hoste et al., 2011).
Psoriasis is a common inflammatory skin disorder mani-
fested in a fine, silvery scaling on the affected skin regions and
characterized by excessive keratinocyte growth, decreased
barrier function (Ghadially et al., 1996), infiltration of neutro-
phils and mononuclear leukocytes (T cells and dendritic cells),
and defective differentiation in the lesional epidermis, result-
ing in parakeratotic plaque formation (reviewed in Bowcock
and Krueger, 2005; Lowes et al., 2007). Parakeratosis is
defined as incomplete cornification in which nuclei and
DNA are still observed in the SC. It occurs in several dermato-
logical disorders, but the molecular mechanisms leading to
parakeratotic plaque formation are largely unknown (Brady,
2004). Although more insight into epidermal DNA catabolism
has been gained during recent years, the process of nuclear
degradation during cornification is still poorly understood
(reviewed in Eckhart et al., 2012). Recently, it has been
shown that repeated topical application of imiquimod (IMQ)
on mouse skin results in an inflammatory cutaneous response
resembling psoriasis (van der Fits et al., 2009; Swindell et al.,
2011). Patients with a strong predisposition to psoriasis show
exacerbation or relapse of psoriatic features upon IMQ
treatment. IMQ binds Toll-like receptor-7 and -8, which are
present on antigen-presenting cells, and upon binding of their
natural or synthetic ligands they activate the innate immune
system to produce several proinflammatory cytokines such as
IFN-g, tumor necrosis factor, IL-6, and IL-12 (Wagner et al.,
1999). As in psoriasis patients, the IL-23/IL-17 axis is of key
importance in IMQ-induced psoriasis-like dermatitis in mice
(van der Fits et al., 2009).
Here, we describe spontaneous ultrastructural abnormalities
in caspase-14-deficient corneocytes pointing to defective or
delayed keratinocyte differentiation. We also show that
caspase-14 / mice are more prone to the development
of parakeratosis upon treatment with IMQ to induce
psoriasis-like dermatitis. These data indicate the impor-
tance of caspase-14 for correct keratinocyte cornification,
especially under challenging conditions that trigger epidermal
hyperproliferation.
RESULTS
Electron microscopic analysis reveals ultrastructural
abnormalities in caspase-14 / skin
Caspase-14 / mice exhibit a defect in the epidermal perme-
ability barrier, and neonates display a shiny and hyper-
lichenified skin (Denecker et al., 2007). As this phenotype is
most prominent in caspase-14 neonates between P1.5 and
P5.5, a detailed electron microscopic analysis was performed
on the skin of newborn wild-type (WT) and caspase-14 /
mice at P3.5 and on adult skin at the age of 9 weeks. At P3.5,
caspase-14-deficient skin frequently contains cells resembling
transitional cells, characterized by disorganized nonhomo-
geneous intracellular content at the stratum granulosum/SC
interface (Figure 1a). In some cases, such cells are found up to
the fourth cornified layer (SC4). Similar but less frequent
incompletely cornified cells were observed in adult caspase-
14-deficient epidermis (Figure 1a). These cells were far less
abundant in WT counterparts. The occurrence of such cells
points to a delay in cornification, although no structural
differences between CEs in WT versus caspase-14 / skin
were apparent (Figure 1b). We assessed whether the observed
structural differences were due to defects in DNA degradation
in caspase-14 / skin by performing TUNEL staining, but
TUNEL-positive cells were scarce in both WT and caspase-
14 / epidermis (data not shown). In addition, by using
Hoechst staining in combination with differential interference
contrast microscopy, we were unable to detect the remaining
DNA in the cornifying layers in both genotypes (Supple-
mentary Figure S1 online). No differences were observed in
extracellular lamellar structures between WT and caspase-
14 / epidermis (data not shown). The structural differences
observed in caspase-14-deficient skin did not affect the
resistance of the skin to tape strip–induced physical damage
compared with WT mice, as evaluated by measuring TEWL
after repeated tape stripping (Supplementary Figure S2 online).
Epidermal caspase-14 deficiency facilitates the formation of
parakeratotic plaques upon topical acetone treatment
Upon repetitive topical treatment with acetone, the epidermis
tries to compensate for the loss in the cutaneous permeability
barrier by increasing the formation of corneocytes (hyper-
keratosis) (Denda et al., 1996). It has been shown that
repeated topical application of acetone removes all stainable
neutral lipids from the cornified layers, thereby disrupting the
skin barrier. This results in an increase in TEWL and causes
a hyperproliferative response (Menon et al., 1985). We
challenged the skin of WT and caspase-14 / mice by
repetitive acetone wipes two times a day for 5 consecutive
days to test whether more pronounced cornification defects
would be present in caspase-14-deficient skin compared with
WT skin. Analysis of hematoxylin–eosin-stained skin sections
demonstrated that repeated acetone treatment induced para-
keratotic plaque formation in the skin of both WT and
caspase-14 / mice (Figure 2). A similar rise of TEWL and
hyperproliferation was observed in the two genotypes upon
acetone treatment (Figure 2b, Supplementary Figure S3
online). Interestingly, the percentage of parakeratotic SC
induced by acetone treatment was higher in caspase-14 /
skin compared with WT skin (Figure 2c). The same trend
was observed when counting parakeratotic plaques larger than
100mm (Figure 2d). Our results indicate that caspase-14
is important for the maintenance of normal keratinocyte
terminal differentiation and SC architecture under skin
barrier–challenging conditions.
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Caspase-14-deficient mice are more prone to the development of
parakeratosis upon induction of psoriasis-like dermatitis
The reported reduction of caspase-14 in psoriatic plaques
(Lippens et al., 2004; Hsu et al., 2007), the observed delay in
cornification in caspase-14 / epidermis (Figure 1), together
with the observation that caspase-14 / mice develop larger
parakeratotic plaques upon acetone treatment (Figure 2), led
us to trigger a psoriasis-like inflammatory response in caspase-
14-deficient skin to investigate whether the lack of caspase-14
facilitates the development of parakeratotic plaques (van der
Fits et al., 2009). We topically treated the back skin of WT
and caspase-14 / mice repeatedly with IMQ to induce a
psoriasis-like skin inflammation. Epidermal scaling was scored
daily by two independent researchers. Scaling of back skin
was apparent in both genotypes after 2 days of IMQ appli-
cation and increased as treatment continued (Figure 3). After
8 days of IMQ treatment, caspase-14 / skin showed marked
scaling compared with the moderate scaling observed in
control skin. Vehicle-treated WT mice exhibited very slight
scaling compared with untreated mice. In contrast, caspase-
14 / skin treated with vehicle cream showed moderate
scaling. The observed increased scaling in caspase-14 /
skin upon topical vehicle or IMQ treatment could point to
a cornification defect in the absence of caspase-14. Indeed,
a larger percentage of SC was parakeratotic in vehicle- or
IMQ-treated caspase-14 / skin relative to WT skin as
observed on hematoxylin–eosin-stained sections (Figure 4a
and b). Notably, vehicle-treated caspase-14 / skin exhibited
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Figure 1. Cornification defects in caspase-14 / newborns and adults. Skin sections of caspase-14þ /þ and caspase-14 / mice at P3.5 days and at the
age of 9 weeks were examined by electron microscopy for stratum corneum (SC) abnormalities. (a) General view of the transitional and cornifying layers in
wild-type (WT) and caspase-14 / skin. Upper panels, bar¼2mm; lower panels, bar¼1mm. (b) Detailed view on the SC1 layer in WT and caspase-14 /
skin at P3.5 days. Arrowheads indicate the cornified envelope. SG, stratum granulosum; SCx, xth layer of cornified cells. Bar¼ 500 nm.
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marked epidermal thickening, due to hyperproliferation
(Supplementary Figure S4 online), in contrast to vehicle-
treated WT skin (Figure 4c). IMQ-treated caspase-14 / mice
had a minor, but statistically significant, increase in skin
thickness compared with WT counterparts after 8 days of
IMQ treatment (Figure 4c). Whether this minor difference is of
biological significance is not clear.
To exclude the possibility that the observed differential
effects are due to a difference in IMQ penetration through the
skin, we analyzed the IMQ concentration in the sera of IMQ-
treated mice of both genotypes. Serum IMQ levels were
similar in WT and caspase-14 / mice (Supplementary
Figure S5a online), indicating that IMQ penetrated equally
through WT and caspase-14 / skin. Consequently, IMQ-
treated caspase-14 WT and caspase-14 / mice showed a
similar degree of splenomegaly (Supplementary Figure S5b
online). It has been shown previously that topical IMQ
treatment results in pronounced splenomegaly in mice
(Palamara et al., 2004; van der Fits et al., 2009). Topical
treatment with vehicle cream did not result in a significant
increase in spleen mass, indicating that the splenomegaly was
solely due to the proinflammatory systemic effects of IMQ.
The greater susceptibility of caspase-14 / skin to the
development of parakeratosis upon IMQ treatment could be
due to differences in the inflammatory status of the skin in
both genotypes. Therefore, we analyzed skin immune cell
infiltrates in both genotypes after topical IMQ treatment.
CD45 leukocytes and CD3 T cells were increased in dermal
and epidermal compartments after 8 days of topical IMQ
treatment (Figure 5a). The area of the surface showing positive
staining was quantified, and no significant difference
was found in the amount of CD45þ cells in WT and
caspase-14 / skin recruited upon IMQ treatment
(Figure 5b). In addition, CD3 staining did not reveal significant
differences in T-cell skin infiltrates between IMQ-treated WT
and caspase-14 / mice (data not shown). Taken together,
all these data indicate that caspase-14 / keratinocytes are
less able to complete the normal cornification program in
hyperproliferative conditions.
Topical IMQ treatment leads to more severe skin barrier
perturbation in caspase-14 / mice
Scaling of skin can be caused by abnormal stacking of corneo-
cytes and leads to impairment of the epidermal permeability
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Figure 2. Caspase-14 / mice develop more and larger parakeratotic plaques upon acetone-induced barrier disruption. (a) Hematoxylin and eosin (H&E)-
stained skin sections of wild-tpe (WT) and caspase-14 / back skin that was left untreated or subjected to repetitive treatment two times daily with saline or
acetone wipes for 5 days. Acetone treatment results in parakeratotic plaque formation in WT and caspase-14 / mice. A representative image of saline (NaCl)-
and acetone-treated skin is shown for both genotypes. Bar¼ 200mm. (b) Transepidermal water loss (TEWL) measurements were recorded 24 hours after the
last treatment. Values of the two genotypes were compared using two-way analysis of variance (ANOVA) testing with Bonferroni post-tests; P-values are indicated
with * (o0.05). (c) Parakeratosis was quantified in all experimental groups on H&E-stained skin sections. Values depicted in the graph are the % of parakeratotic
stratum corneum (SC) surface. These data were statistically analyzed by a logistic regression model as explained in Materials and Methods. Bars represent mean
values±SEM. WT untreated: n¼10; knockout (KO) untreated: n¼ 10; WT NaCl: n¼10; KO NaCl: n¼ 10; WT acetone: n¼ 16; KO acetone: n¼ 16. The total
length of skin analyzed was 107.75 mm in WT untreated; 95.25 mm in KO untreated; 78.5 mm in WT NaCl; 111 mm in KO NaCl; 252.25 mm in WT acetone; and
351.75 mm in KO acetone. (d) Mice treated as in c were analyzed for the number of parakeratotic plaques larger than 100mm over a total section length of 10 cm.
Only statistically significant differences are indicated by asterisks (b and c).
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barrier (Elias et al., 2004). We show that topical IMQ
treatment initially led to an increased TEWL in both
genotypes, observed from day 4 of treatment (Figure 6). After
8 days of IMQ treatment, a significant difference in TEWL
between WT and caspase-14 / mice was observed, pointing
to a more severe skin barrier perturbation in the absence of
epidermal caspase-14. Notably, TEWL measurements were
also significantly higher in caspase-14 / mice treated with
vehicle cream compared with vehicle-treated WT mice or
untreated mice (Figure 6). This observation shows that
inflamed caspase-14-deficient skin is more susceptible to
barrier perturbation. As mentioned in the previous section,
the same trend was observed for epidermal thickness and
parakeratotic lesions (Figure 4b and c).
DISCUSSION
Generation of caspase-14-deficient mice led to the identifica-
tion of caspase-14 as an important factor in proper SC
formation. A basal increase in TEWL was observed in newborn
caspase-14 / mice concomitant with a decreased SC
hydration level (Denecker et al., 2007). Here, we performed
detailed electron microscopic analysis revealing ultrastructural
defects in caspase-14 / newborn and adult epidermis
(Figure 1). The higher incidence of incompletely cornified
cells in the transitional layer of caspase-14 / epidermis
points to a delay in terminal keratinocyte differentiation,
although the CEs appeared normal in caspase-14 / skin.
These transitional cells resemble those observed during
prolonged occlusion after tape stripping (Ahn et al., 1999),
or after tape stripping of caspase-14 / mice (Demerjian
et al., 2008). In contrast to these previous studies, we did not
observe clear remnants of the degrading nucleus or other
cellular organelles in these cells. In spite of the fact that
Hibino and co-workers (2010) reported that activated caspase-
14 colocalizes with TUNEL-positive cells in human epidermis,
we did not observe obvious differences in TUNEL-positive cell
numbers when comparing WT and caspase-14 / epidermis
(data not shown). We previously showed that caspase-14 is
needed to degrade (pro)filaggrin into natural moisturizing
factors, such as urocanic acid and 2-pyrrolidone-5-
carboxylic acid (Denecker et al., 2007; Hoste et al., 2011).
Flaky tail mice, which are filaggrin deficient, and therefore
have reduced natural moisturizing factor levels, exhibit
impaired lamellar body secretion and have abnormal extra-
cellular lamellae (Scharschmidt et al., 2009). However,
differences in the incidence of transitional cells were not
reported in these mice, nor in filaggrin-deficient patients. This
indicates that the delay in cornification observed in caspase-
14 / skin is probably due to unknown caspase-14 substrates
other than (pro)filaggrin, contributing to this phenotype. Why
incompletely cornified cells were observed less frequent in
adult caspase-14 deficient mice is currently not clear. How-
ever, this could be due to higher epidermal proliferation rates
in neonatal mice than in adult mice. The ultrastructural
differences observed in caspase-14-deficient skin further
illustrate the important role for caspase-14 in proper
keratinocyte cornification.
Epidermal barrier disruption can induce a new wave of
cornification to compensate for the loss of permeability barrier
function (Demerjian et al., 2008). To test the effect of caspase-
14 ablation on this process, we disrupted the epidermal barrier
by repetitive topical acetone application. Compared with WT
skin, the percentage of parakeratotic skin was significantly
increased in caspase-14 / mice (Figure 2c). In addition,
caspase-14 / mice showed a marked increase in large
parakeratotic plaques (Figure 2d). This is in accordance
with the observation that correct keratinocyte cornification
was highly attenuated in transitional cells in tape-stripped
caspase-14 / skin (Demerjian et al., 2008).
Psoriatic skin contains a large number of infiltrating immune
cells that produce many different inflammatory molecules.
This results in epidermal hyperproliferation, parakeratosis, and
a defective epidermal barrier (reviewed in Roberson and
Bowcock, 2010). Clinical topical use of IMQ can elicit
psoriasis in patients predisposed to the disease. When it is
applied repetitively on murine back skin, it induces a
psoriasis-like phenotype, fulfilling many criteria for a valid
psoriasis mouse model (Conrad and Nestle, 2006; van der Fits
et al., 2009; Wagner et al., 2010; Swindell et al., 2011).
Nevertheless, no single mouse model for psosiaris
recapitulates all human pathology features of the disease
(Wagner et al., 2010; Swindell et al., 2011). Repeated
topical IMQ treatment of WT and caspase-14 / mice
resulted in a higher degree of scaling, TEWL, and
parakeratotic SC in caspase-14 / mice relative to controls
(Figures 3–6). The more severe barrier perturbation in caspase-
14 / mice can be due to the higher degree of parakeratosis
observed in these mice. How the absence of caspase-14
facilitates parakeratosis upon epidermal barrier challenge is
currently not clear. One possibility is that caspase-14 has a
role in the enucleation process or DNA degradation during
terminal keratinocyte differentiation in inflammatory condi-
tions, but not under homeostatic conditions (cfr. absence of a
spontaneous phenotype in caspase-14 / mice). The inter-
action of the keratinocytes with mononuclear leukocytes is of
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Figure 3. Caspase-14 / mice are more sensitive to vehicle- and imiquimod
(IMQ)-induced epidermal scaling than wild-type (WT) mice. Scaling of the
epidermis was scored independently by two researchers on a scale from 0 to 4:
0, none; 1, slight; 2, moderate; 3, marked; and 4, very marked. WT untreated:
n¼ 4; knockout (KO) untreated: n¼ 4; WT vehicle: n¼ 6; KO vehicle: n¼6;
WT IMQ: n¼ 11; and KO IMQ: n¼ 12. All values from both genotypes
were compared using two-way analysis of variance (ANOVA) testing with
Bonferroni post-tests. Bars represent mean values±SEM. P-values are indicated
with *** (o0.001). Only statistically significant differences are indicated by
asterisks.
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key importance for the development of psoriatic lesions
(reviewed in Armstrong et al., 2011), but no difference was
observed in infiltrating leukocyte or T-cell numbers between
IMQ-treated WT and caspase-14 / skin. The difference in
parakeratotic plaque formation in caspase-14-deficient skin
was not due solely to the IMQ treatment, because an increase,
although less extensive, in epidermal thickness, parakeratosis,
and TEWL was also observed upon topical treatment of these
mice with vehicle cream, which was not the case in control
mice (Figure 6). The exact reason for this differential effect of
control cream on WT and caspase-14 / mice is currently
not clear, but could be due to a higher sensitivity to friction-
induced stress (cfr. repetitive treatment) or to an altered
penetration efficacy of the control cream in caspase-14 /
mice compared with WT mice.
Hyperproliferating skin requires an enhanced differentiation
rate to keep the epidermis in check. Apparently, in such
conditions, caspase-14-deficient skin encounters more diffi-
culties in achieving proper SC formation and barrier main-
tenance compared with normal skin. This suggests that the low
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Figure 4. Caspase-14 / mice are more prone to the development of parakeratosis than their wild-type (WT) counterparts upon topical imiquimod (IMQ)
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levels of caspase-14 expression or activation observed in
psoriatic parakeratotic lesions (Lippens et al., 2000, 2004;
Fischer et al., 2004; Raymond et al., 2007) were a cause rather
than a consequence of parakeratosis. The lowered caspase-14
expression levels in psoriatic skin could be due to the action of
T-helper type 1 cytokines, which were shown to downregulate
caspase-14 expression (Hvid et al., 2011). Moreover, treat-
ment of lesional psoriatic skin with vitamin D3 analogs does
ameliorate psoriatic plaque morphology and re-establishes
normal caspase-14 expression levels (Lippens et al., 2004).
When comparing IMQ-induced psoriasis-like conditions in
murine skin with psoriatic lesions in patients, it is important to
keep in mind that multiple differences exist between murine
and human skin (Swindell et al., 2011). It should also be noted
that the psoriasis-like phenotype induced by topical IMQ
application shares features with other inflammatory skin
disorders, such as atopic eczema. Psoriatic lesions share
several characteristics with wound healing responses, and
hence it would be interesting to investigate whether ablation
of epidermal caspase-14 affects atopic dermatitis or wound
healing dynamics. Interestingly, caspase-14 activity levels are
reduced in atopic dermatitis skin (Yamamoto et al., 2011).
In summary, we show that caspase-14 deficiency leads to a
delay in keratinocyte cornification in homeostatic conditions,
which may affect epidermal barrier function under basal
conditions. In addition, we clearly demonstrate that caspase-
14 activity protects against loss of skin permeability upon
challenging of the cutaneous barrier and against development
of parakeratotic plaques in IMQ-induced psoriasis-like epi-
dermal dermatitis. Therefore, our results underscore the
important role of caspase-14 in terminal keratinocyte differen-
tiation and identify caspase-14 downregulation as an impor-
tant facilitating factor in developing parakeratotic plaques in
inflammatory skin conditions. These findings point to the
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represent mean values±SD. Wild-type (WT) untreated: n¼ 4; knockout (KO)
untreated: n¼4; WT vehicle: n¼ 6; KO vehicle: n¼ 6; WT IMQ: n¼11;
and KO IMQ: n¼ 12. Values of the two genotypes were compared using
two-way analysis of variance (ANOVA) testing with Bonferroni post-tests;
P-values are indicated with * (o0.05), ** (0.05–0.001), or *** (o0.001).
Only statistically significant differences are indicated by asterisks.
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Figure 5. Imiquimod (IMQ)-treated wild-type (WT) and caspase-14 /
skin have similar numbers of infiltrating leukocytes. (a) Back skin sections
of untreated, vehicle-treated, and IMQ-treated caspase-14þ /þ and
caspase-14 / mice were probed with anti-CD45 antibody. A representative
image is shown for each condition. Bar¼40mm. (b) Quantification of
diaminobenzidine (DAB) positivity in stained skin sections is represented as
DAB-positive area as a percent of total area (epidermis and dermis). Three
sections per mouse sample were analyzed. WT untreated: n¼12; knockout
(KO) untreated: n¼ 12; WT vehicle: n¼ 18; KO vehicle: n¼ 18; WT IMQ:
n¼ 31; and KO IMQ: n¼ 34. Values of the two genotypes were compared
using a logistic regression model as explained in Materials and Methods.
Bars represent mean values±SEM. We could not observe statistically
significant differences between the two genotypes.
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putative beneficial effects of therapies that could re-establish
caspase-14 expression in conditions of parakeratosis or barrier
disruption.
MATERIALS AND METHODS
Mice
Caspase-14þ /þ and caspase-14 / mice have been described
previously (Denecker et al., 2007). Mice were kept under specific
pathogen-free conditions, and all procedures were approved by the
institutional ethics committee.
Scoring of epidermal scaling
Arbitrary scores were given for skin scaling, as described previously
(van der Fits et al., 2009). Epidermal scaling was scored indepen-
dently by two researchers on a scale from 0 to 4: 0, none; 1, slight; 2,
moderate; 3, marked; and 4, very marked.
Tissue preparation for electron microscopy
Back skin from WT and caspase-14 / mice at the ages of 3.5 days
and 9 weeks was immersed in a fixative solution of 2.5% glutaral-
dehyde, 3% formaldehyde, and 0.02% CaCl2 in 0.1 M Na-cacodylate
buffer, placed in a vacuum oven for 30 minutes and then left rotating
for 3 hours at room temperature. This solution was later replaced with
fresh fixative, and samples were left rotating overnight at 4 1C. After
washing, samples were postfixed in 1% OsO4 with K3Fe(CN)6 in
0.1 M Na-cacodylate buffer, pH 7.2. Samples were dehydrated
through a graded ethanol series, including a bulk staining with 2%
uranyl acetate at the 50% ethanol step, followed by embedding in
Spurr’s resin. To have a larger overview of the phenotype, semithin
sections were first cut at 0.5 mm and stained with toluidine blue.
Ultrathin sections of a gold interference color were cut using an
ultramicrotome (Leica EM UC6, Wetzlar, Germany), followed by
poststaining with uranyl acetate and lead citrate in a Leica EM AC20
and collected on formvar-coated copper slot grids. They were viewed
with a transmission electron microscope JEOL 1010 (JEOL, Tokyo,
Japan).
Topical IMQ application
Female mice at the age of 8 to 12 weeks were shaved with clippers
(Wella contoura, Bio-services, The Netherlands) and a close shaving
device (EpiLady, Philips, Belgium). Topical IMQ treatment (125 mg
Aldara (3M Pharmaceuticals, Diegem, Belgium), containing 5% of
IMQ) was started 48 hours after shaving and was repeated daily for 8
consecutive days (modified from van der Fits et al., 2009). The IMQ
dose causing the most reproducible skin inflammation in WT and
caspase-14 / mice was empirically determined (data not shown).
Vehicle cream contained the same ingredients as IMQ-containing
cream. On the days indicated, mice were killed by cervical
dislocation and back skin was isolated for further processing.
Acetone-induced skin barrier disruption
Acetone or control saline treatment was performed two times a day
(morning and evening). Acetone was applied by wiping shaved back
skin five times with a paper cloth soaked in acetone or 1 M NaCl.
Analysis of parakeratosis
Paraffin sections of skin samples were stained with hematoxylin and
eosin. Parakeratosis was independently assessed by two researchers
using a light microscope. The length of parakeratotic plaques was
measured using a ruler ocular. For parakerotosis data, expressed as %
of affected SC as determined on skin sections, a logistic regression
model of the Yijk¼ mþ genotypejþ treatmentkþ errorijk was fitted
to the data, partitioning the parakerototic cell number variation
into fixed genotype and treatment effects, and random error
effects. The regression line was assessed by comparing its deviance
with w2. All analyses were performed by means of GenStat v.14
(Payne, 2011).
Immunohistochemical analysis of skin sections
Monoclonal rat anti-mouse Ki-67 antibody (Dako Cytomation,
Heverlee, Belgium; Clone TEC-3) was used at a 1/30 dilution to
analyze the proliferative status of the epidermal keratinocytes. Ki-67-
positive keratinocytes in the interfollicular epidermis were manually
counted or automated analysis was performed by determining the
percentage of diaminobenzidine (DAB)-stained area as explained
below. Rat anti-mouse CD45 antibody (Becton Dickinson Benelux,
Erembodegem, Belgium; cat. no. 550539) and rabbit anti-mouse CD3
antibodies (Abcam, Cambridge, UJ; cat. no. ab5640) were used at a
dilution of 1:100. The number of mice that were analyzed were as
follows: WT untreated, n¼ 4; caspase-14 / (knockout (KO))
untreated, n¼ 4; WT vehicle day 8, n¼ 6; KO vehicle day 8, n¼ 5;
WT IMQ day 8, n¼ 9; and KO IMQ day 8, n¼ 10. Three sections per
mouse were analyzed. To quantify the amount of CD45-positive cells,
we determined the percentage of DAB-stained area in each image.
The area of the section was manually segmented (epidermisþ dermis)
with Volocity image analysis software (Perkin-Elmer, Waltham, MA).
Within this segment, the DAB-positive cells were identified using a
RGB threshold. The percentages of DAB-stained pixel count area
(100 DAB-stained pixel area divided by the section pixel area)
were calculated for all images, and the results were plotted and
statistically analyzed with the GraphPad software using two-way
analysis of variance (ANOVA) with Bonferroni post-testing.
Measurement of TEWL
Mice were anesthetized by intraperitoneal injection of a ketamine/
xylazine mixture. TEWL was measured using a TEWA meter (Courage
and Khazaka, Cologne, Germany; TM 210). Data were analyzed for
statistical significance with the GraphPad Prism 5.0 software using
two-way ANOVA with Bonferroni post-testing.
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